The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Efficacy of anti-tumor necrosis factor therapy in patients with ulcerative colitis
Abstract
OBJECTIVES: Tumor necrosis factor-alpha (TNF-alpha) is an important cytokine involved in the pathogenesis of inflammatory bowel disease. The monoclonal antibody to TNF-alpha, infliximab, is effective in treating Crohn's disease. Preclinical studies suggest the importance of TNF-alpha in treating ulcerative colitis (UC). We report the effectiveness of infliximab for UC and examine factors predictive of response to medication. METHODS: Data from all UC patients receiving infliximab at four institutions were analyzed. Disease activity was determined by the Disease Activity Index. RESULTS: A total of 27 patients with active UC received inpatient (37%) and outpatient (63%) infliximab as single (52%) or multiple (two to 15) infusions (48%). Twelve patients (44%) achieved remission and six patients (22%) had partial response. Nine patients had no response; five subsequently underwent total colectomy. The median time to achieve response and remission was 4 days and the median duration 8 wk. Nine of the 18 patients who responded experienced 19 relapses; 18 of these relapses (95%) were successfully treated with repeat infusions. Steroid-refractory patients were less likely to respond to infliximab therapy than were steroid-responsive patients (33% vs 83%; p = 0.026). No other factors were predictive of response to infliximab. Two patients developed serious adverse events, including death in one case. CONCLUSIONS: Preliminary evidence suggest effectiveness of infliximab in the treatment of UC, including medically refractory severe disease. Individuals who are refractory to corticosteroids, however, may be unlikely to respond to infliximab. A randomized controlled trial is necessary to further investigate the efficacy of infliximab in patients with UC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Targan, S. R., Hanauer, S. B., van Deventer, S. J. H., Mayer, L., Present, D. H., Braakman, T., DeWoody, K. L., Schaible, T. F., & Rutgeerts, P. J. (1997) · New England Journal of Medicine · doi:10.1056/nejm199710093371502 · Cited by 3,135
Reimund, J. M., Wittersheim, C., Dumont, S., Muller, C. D., Baumann, R., Poindron, P., & Duclos, B. (1996) · Journal of Clinical Immunology · doi:10.1007/bf01540912 · Cited by 281
Cited by
Laharie, D., Bourreille, A., Branche, J., Allez, M., Bouhnik, Y., Filippi, J., Zerbib, F., Savoye, G., Nachury, M., Moreau, J., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61084-8 · Cited by 646
Ardizzone, S., Maconi, G., Russo, A., Imbesi, V, Colombo, E., & Bianchi Porro, G. (2006) · Gut · doi:10.1136/gut.2005.068809 · Cited by 505
A porous defense: the leaky epithelial barrier in intestinal disease
Clayburgh, D. R., Shen, L., & Turner, J. R. (2004) · Laboratory Investigation · doi:10.1038/labinvest.3700050 · Cited by 498
Optimizing anti-TNF treatment in inflammatory bowel disease
Rutgeerts, P., van Assche, G., & Vermeire, S. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.02.070 · Cited by 429
Probert, C. S. J., Hearing, S. D., Schreiber, S., Kühbacher, T., Ghosh, S., Arnott, I. D. R., & Forbes, A. (2003) · Gut · doi:10.1136/gut.52.7.998 · Cited by 355
Metadata
- Authors
- Su, C.
- Venue
- The American Journal of Gastroenterology
- Published
- 2002-10
- Volume
- 97
- Issue
- 10
- Pages
- 2577-2584
- ISSN
- 0002-9270 (ISSN-L)
- OpenAlex
- W2066526978
- Cited by
- 175
- References
- 2
- FWCI
- 12.01
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy of anti-tumor necrosis factor therapy in patients with ulcerative colitis. https://app.cochat.ai/papers/10.1016/s0002-9270(02)04384-8
- The paper
- Su, C. (2002). Efficacy of anti-tumor necrosis factor therapy in patients with ulcerative colitis. The American Journal of Gastroenterology. https://doi.org/10.1016/s0002-9270(02)04384-8
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.